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Conclusions: EPIC-CP was highly endorsed from healthcare 
practitioners and prostate patients across participating cancer 
centres. The EPIC-CP tool captures prostate-specific symptom 
information that assists in enhancing clinical care and symptom 
management. Provincial roll-out of EPIC-CP as a standard of care 
for PROs in clinical practice is recommended. 
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Purpose: To determine the preferences of radiation oncologists 
in Canada for treatment of low-risk and intermediate-risk 
prostate cancer in an era when no “gold standard” has been 
defined. 
Methods and Materials: A 20-item email questionnaire was sent 
to all practising radiation oncologist in Canada. Responses were 
collected over a four-week interval and are reported 
anonymously as aggregate. 
Results: Thirty-three responses were collected from 10 
provinces. All but two respondents treated prostate cancer 
routinely and saw between six and 30 new patients per month. 
Seventeen out of 31 (55%) prostate cancer treating respondents 
indicated they recommended active surveillance (AS) more 
frequently now compared to five years ago, whereas eight (26%) 
have not made a change in practice. Twenty-two (68%) 
respondents cited the Klotz criteria (PSA ≤ 10ng/mL, Gleason 
score of ≤ 6 or age ≥ 70 years and PSA ≤ 15 and Gleason score of 
≤ 3 + 4) or patient preference as reasons for offering AS. Twenty-
five (81%) would first recommend AS for low-risk prostate cancer. 
Almost all respondents would take the patient off AS for disease 
progression of any type (pathologic, clinical, or biochemical) or 
if the patient decided for treatment with no progression of 
disease. Twenty-two (69%) felt radical prostatectomy (RP) and 
brachytherapy (BT) were equivalent. Two (6%) felt cure rates 
were better with RP and eight (25%) felt BT cure rates were 
better. Eighteen (56%) of respondents would only recommend BT 
to patients with intermediate-risk prostate cancer; nine (28%) 
would outline options of BT, RP and external beam radiotherapy 
(EBRT). If BT was not a treatment option, then 18 (56%) 
respondents would support RP over EBRT. 
Conclusions: This survey confirmed that AS is more strongly 
favoured across Canada by radiation oncologists who treat low 
and select intermediate-risk prostate cancer. BT and RP continue 
to be the preferred recommendations. There was a bias towards 
belief that BT cure rates are better despite the lack of 
randomized evidence. EBRT is felt by most to be less curative 
than either RP or BT. 
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Purpose: To determine the maximum tolerated dose (MTD) of 5 
fraction stereotactic radiosurgery (SRS) delivered with 
concurrent and adjuvant temozolomide (TMZ) in newly diagnosed 
glioblastoma multiforme (GBM).  
Methods and Materials: Adult patients with newly diagnosed 
GBM were treated with escalating doses of SRS in a 3+3 design on 
4 dose levels: 25 Gy, 30 Gy, 35 Gy, and 40 Gy targeting the 
cavity/residual tumour with a 5 mm CTV margin and 0 mm PTV. 
There were 2 arms per PTV size: < 60 cm3 (Arm 1) and 60-150 cm3 
(Arm 2). A dose limiting toxicity (DLT) was defined as CTCAE 
Grade 3-5 CNS toxicity within 30 days of SRS, with life-long 
assessment for late SRS-related adverse radiation effect (ARE). 
The maximum tolerated dose (MTD) was the highest dose where 
0-1 out of six had an acute or late CNS Grade 3-5 toxicity. 
Secondary endpoints included progression free survival (PFS) and 
overall survival (OS). Given the difficulty in interpreting post-SRS 
imaging, any new enhancement was scored as: 1) tumour 
progression, if ultimately determined to be recurrent tumour 
(PD); 2) transient ARE if occurred within five months and 
resolved (i.e., pseudoprogression, PP); 3) persistent ARE (i.e., 
radionecrosis, RN). All AREs were scored per CTCAE.  
Results: From 2010 to 2015, 30 total patients were enrolled. The 
median age was 66 with median KPS of 80. The median GTV was 
26.8 cc (range 3.8–81.0 cc) with a PTV of 60.2 cc (range 14.7–
137.3). Protocol defined DLTs occurred in 2 patients: one 
admitted for PD at 3 weeks (Grade 4, Arm 2, Dose 40 Gy); another 
patient died 1.5 weeks post-SRS from suspected post-operative 
complications (Grade 5, Arm 1, Dose 40 Gy). AREs occurred in 11 
patients: five cases of PP occurring at a median time of 2.8 
months from SRS (range 0.8-3.4); 6 cases of RN (Grade 1 n = 2, 
Grade 2 n = 4) at 6.9 months (range 3.2–12.6). All patients with 
PP and all but one with RN had MGMT methylated tumours. 
Extent of resection (HR 0.19) and MGMT methylation (HR 0.36) 
were associated with improved OS on multivariate analysis. RN 
was not associated with increase in dose, GTV or PTV volume. 
Ultimately, 25 (83%) of patients were treated with bevacizumab, 
started in 17% for symptomatic transient ARE, 6% for persistent 
ARE, and 60% for PD. With a median follow up of 12.9 months, 
the median OS for all patients was 15.0 months, with a median 
PFS of 6.37 months. Median OS was 20.0 months for patients with 
MGMT methylated tumours, versus 11.3 months for MGMT 
unmethylated (p = 0.046). Presence of RN was associated with 
improved median OS (33.2 versus 11.3 months; p = 0.024). 
Amongst MGMT methylated patients who developed RN, median 
OS was 33.5 versus 16.9 months for those without RN (p = 0.10).  
Conclusions: The primary endpoint of dose escalation to 40 Gy 
was achieved without severe treatment-related toxicity. 
However, a dose recommendation based on tumour size cannot 
be made. These results suggest that SRS with concurrent TMZ 
constitutes a safe and feasible treatment for GBM with OS 
comparable to conventional fractionation. 
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Purpose: To assess adequacy of a Foley catheter for urethral 
delineation for evaluation of urethral dose in high-dose rate 
prostate brachytherapy(HDR-PB). 
Methods and Materials: Twenty-one sets of prostate ultrasound 
images were recorded with and without a Foley catheter in 
place. The first images were obtained during HDR-PB for 
intraoperative planning with a Foley catheter in-situ. A standard 
6mm-diameter circle was used to delineate the catheter on 
transverse images, assuming that it represented the urethra. 
Dosimetric optimization parameters were Prostate V100%≥98%, 
V125%: 55-62% and D90% ≥ 100% and urethral V115% = 0 cc. After 
treatment, another set of images was recorded after removing 
the catheter and instilling aerated gel into the urethra without 
removing the brachytherapy needles or changing the patient’s 
position. The images were fused using either Vitesse3.0 or 
BrachyVision11.0. Urethral dosimetric parameters, position and 
volume of the urethra were compared. Paired Student’s t-tests 
were performed for statistical analysis. 
Results: Images were recorded on 16 intermediate to high-risk 
prostate cancer patients who received HDR-PB boost combined 
with 46 Gy/23 fractions external beam radiotherapy. Eight had 
two fractions of 10 Gy in separate implants and the remaining 
eight received 15 Gy in one fraction. Twenty-one paired sets of 
